Triglycerides are the most common form of fat in your blood. They reflect how your body handles carbohydrates, alcohol, and calories — making them a direct window into metabolic health and insulin sensitivity. Elevated triglycerides don't just sit passively; recent Mendelian randomization evidence shows they drive atherosclerotic cardiovascular disease via triglyceride-rich lipoprotein remnants (VLDL and small dense LDL particles), making this marker both a symptom of metabolic dysfunction and a causal contributor to heart disease.
Analyzed in accredited Swedish clinical laboratories (ISO 15189). Used to support clinician-directed evaluation and monitoring. Not a stand-alone diagnosis.
Triglycerides reveal how efficiently your body processes carbohydrates and fats. If you have family history of heart disease, metabolic syndrome, diabetes, or obesity, your triglyceride level is a critical early-warning signal. Most standard vårdcentral bloodwork includes a fasting triglyceride measure, making it highly accessible.
The real power of triglyceride testing is that it exposes metabolic dysfunction that other markers miss. Many people with normal LDL cholesterol still have dangerously elevated triglycerides — a pattern that significantly increases cardiovascular risk. Because elevated triglycerides often precede visible changes in weight, glucose, or blood pressure, testing them gives you years of lead time to intervene.
Reveals metabolic carbohydrate handling. Elevated triglycerides are the bloodwork fingerprint of poor insulin sensitivity and excessive hepatic lipogenesis — the hallmark of metabolic dysfunction before diabetes develops.
Identifies hidden cardiovascular risk. Even with normal LDL cholesterol, elevated triglycerides signal atherogenic VLDL and remnant particles that predict cardiovascular events. This discordance is common and clinically critical.
Flags pancreatitis risk at extreme levels. Triglycerides above 10 mmol/L create acute pancreatitis risk and demand urgent intervention — they're one of the few biomarkers where a single extreme result triggers emergency action.
Tracks response to lifestyle and dietary change. Triglycerides respond faster than most lipid markers to reduced refined carbohydrate and alcohol intake, weight loss, and increased aerobic training — making them sensitive for early feedback.
Contextualizes other metabolic markers. Elevated triglycerides alongside elevated HbA1c, low HDL, or elevated blood pressure confirms metabolic syndrome — a clustering pattern that multiplies individual risk.
Guides personalized intervention strategy. High triglycerides with normal ApoB suggests dietary carbohydrate and alcohol excess; high triglycerides with elevated ApoB suggests more entrenched metabolic dysfunction requiring pharmacology. The pattern matters.
Non-fasting triglycerides are more realistic. Post-prandial (non-fasting) triglyceride elevation >2.0 mmol/L is a stronger predictor of cardiovascular events than fasting levels, making this marker increasingly useful for real-world testing protocols.
Triglycerides are three-chain fat molecules that your body uses for energy storage and transport. When you eat carbohydrates, alcohol, or calories, your liver packages them into triglycerides and ships them out into the bloodstream inside VLDL (very low-density lipoprotein) particles. Between meals, your fat cells release triglycerides via the bloodstream for muscle and brain to burn. This system works fine when insulin sensitivity is normal and calorie balance is maintained. But when insulin resistance develops — whether from excessive carbohydrate intake, obesity, sedentary behavior, or genetic predisposition — the liver's brake on triglyceride production breaks. It pumps out VLDL continuously, flooding your blood with triglycerides.
Why elevated triglycerides drive atherosclerosis. Triglyceride-rich lipoproteins (VLDL and their remnants, IDL particles) are small enough to penetrate the arterial endothelium and deposit lipids in the artery wall. Once inside, they become oxidized and trigger an inflammatory cascade that hardens into plaque. This atherogenic pathway is now proven causal via Mendelian randomization — genes that raise triglycerides causally increase heart disease risk, not just as a marker but as an actual driver. ApoB-containing remnant particles from triglyceride-rich metabolism are among the most potent atherogenic particles in circulation, which is why the European guidelines now target both ApoB (particle count) and triglycerides (metabolic load) together.
The insulin resistance link. Elevated triglycerides are almost always a sign of insulin resistance. When muscle and liver cells become resistant to insulin's signal, the pancreas pumps out more insulin to compensate. High insulin suppresses the hormone-sensitive lipase that breaks down stored fat, while simultaneously telling the liver to synthesize more triglycerides from dietary carbohydrate. The result is a vicious cycle: more fat storage, more VLDL production, higher triglycerides, and worsening metabolic dysfunction. This is why triglycerides are such a powerful proxy for whole-body carbohydrate and metabolic handling.
Single best-accessible marker of metabolic health. Among commonly tested markers, triglycerides capture more about your metabolic phenotype — carbohydrate handling, hepatic lipogenesis, insulin sensitivity — than almost any other. It's a functional summary of metabolic state, not just a risk factor.
Reveals atherogenic lipoprotein remnants. Elevated triglycerides signal the presence of VLDL and remnant particles that are causally atherogenic via ApoB content. Ignoring them in favor of LDL alone misses a major driver of cardiovascular disease, especially in insulin-resistant individuals.
Responds predictably to intervention. Triglycerides drop reliably when insulin sensitivity improves — through reduced refined carbohydrate intake, weight loss, and aerobic training. This makes them an early feedback signal that your metabolic interventions are working, sometimes before weight or glucose change visibly.
Identifies people at pancreatitis risk. At levels >10 mmol/L, triglycerides create acute pancreatic inflammation and lipotoxicity risk. This is one of the few biomarker thresholds where a single abnormal result mandates emergency action.
Standard Swedish reference (vårdcentralen, fasting): <1.7 mmol/L is considered normal. Levels 1.7–2.3 mmol/L are borderline elevated.
Loovi optimal (longevity, fasting): <1.0 mmol/L. This reflects optimal metabolic health and minimizes remnant atherogenicity risk.
High and very high: >2.3–5.6 mmol/L is clinically high; >5.6 mmol/L is very high and signals substantial metabolic dysfunction.
Acute pancreatitis threshold: >10 mmol/L creates acute lipemia and pancreatitis risk — this is an emergency threshold.
Non-fasting values: Post-prandial (non-fasting) triglycerides >2.0 mmol/L associate with elevated cardiovascular risk and increasingly predict events better than fasting values. Modern evidence suggests measuring non-fasting triglycerides in real-world settings (within 4 hours of a normal meal).
The jump from <1.7 mmol/L to <1.0 mmol/L reflects the shift from “not sick” to “optimally healthy.” At Loovi's <1.0 threshold, the atherogenic VLDL and remnant burden is minimal, and metabolic health is confirmed. Fasting versus non-fasting matters clinically — if you're tested fasting, aim for <1.0 mmol/L; if non-fasting, <1.5 mmol/L is a reasonable target, though <2.0 is still acceptable. Don't let a normal fasting triglyceride falsely reassure you if your postprandial level is elevated.
Low triglycerides (<1.0 mmol/L). This reflects excellent metabolic health. Your liver is not overproducing VLDL, your insulin sensitivity is normal, and your dietary pattern is supporting metabolic fitness. Low triglycerides also mean minimal atherogenic remnant particles and reduced cardiovascular risk from this pathway. Very low triglycerides (<0.5 mmol/L) are also normal and simply reflect low carbohydrate intake or high aerobic fitness; they don't signal a problem.
Borderline-high triglycerides (1.0–1.7 mmol/L). This is the zone where metabolic dysfunction may be emerging. Insulin sensitivity is beginning to slip, hepatic triglyceride production is rising, and remnant particle burden is increasing. This is the moment to intervene with dietary change and training — before the pattern worsens. If you have family history of heart disease, ApoB elevation, or other metabolic markers trending badly, borderline triglycerides demand attention.
High triglycerides (1.7–2.3 mmol/L). This pattern confirms metabolic dysfunction. Insulin resistance is present, VLDL overproduction is active, and atherogenic remnant particles are abundant. Cardiovascular risk is elevated, especially if ApoB is also high or HDL is low. This is the zone where pharmaceutical intervention (usually a fibrate or high-dose statin) often enters the conversation alongside dietary and lifestyle change.
Very high triglycerides (2.3–5.6 mmol/L). Significant metabolic disease is present — often metabolic syndrome, severe insulin resistance, or secondary causes (poorly controlled diabetes, hypothyroidism, alcohol excess). Atherogenic burden is substantial. At this level, rapid intervention is warranted, usually combining dietary change, weight loss, exercise, and medication. If triglycerides are this elevated alongside other metabolic markers, consultation with a longevity doctor is urgent.
Critical level (>5.6 mmol/L, especially >10 mmol/L). Extremely elevated triglycerides signal severe metabolic derangement and acute pancreatitis risk. This requires immediate medical attention. At >10 mmol/L, blood becomes visibly lipemic and pancreatic inflammation risk is acute. Hospitalization may be warranted. These levels demand urgent investigation for secondary causes (severe uncontrolled diabetes, genetic dyslipidemia, severe kidney disease, medication side effects) and aggressive treatment.
Factors that influence triglycerides. Recent alcohol intake raises triglycerides for hours and days afterward. High dietary carbohydrate, especially refined carbs and added sugars, drives hepatic triglyceride synthesis. Intense aerobic exercise within the prior 48 hours can transiently lower triglycerides. Pregnancy and hormonal contraceptives can raise triglycerides 20–100%. Hypothyroidism, uncontrolled diabetes, kidney disease, and some medications (estrogens, corticosteroids, beta-blockers, antipsychotics) raise triglycerides. Fasting state matters: fasting triglycerides underestimate the true metabolic burden if your postprandial pattern is chronically elevated. For the most honest reading of your metabolic state, a non-fasting measurement (within 4 hours of a normal meal) is increasingly recommended by the ESC.
Insulin resistance and metabolic syndrome. The primary driver of elevated triglycerides in metabolic populations. When muscle and liver cells become insulin resistant, the pancreas compensates with hyperinsulinemia, which suppresses fat breakdown and drives hepatic triglyceride synthesis. This is why triglycerides rise in tandem with obesity, sedentary behavior, excessive refined carbohydrate intake, and lack of aerobic fitness.
Dietary carbohydrate and alcohol excess. The liver converts excess dietary carbohydrate and alcohol into triglycerides via de novo lipogenesis. High-carbohydrate, high-alcohol diets that exceed energy expenditure directly elevate hepatic VLDL production. This effect is potent and dose-dependent — removing refined carbs and alcohol often lowers triglycerides within weeks.
Genetic predisposition (familial hypertriglyceridemia). Some people inherit genes that increase VLDL production (familial hypertriglyceridemia) or reduce triglyceride clearance (lipoprotein lipase deficiency). Genetic forms are rarer but can produce extreme triglyceride levels unresponsive to lifestyle alone. Family history of early heart disease or extremely elevated triglycerides should prompt investigation for genetic forms.
Secondary causes. Uncontrolled diabetes (high glucose drives hepatic lipogenesis), hypothyroidism (slows triglyceride clearance), kidney disease (disrupts lipoprotein metabolism), and autoimmune disease can all elevate triglycerides. Estrogen-containing medications (contraceptives, hormone therapy) and corticosteroids reliably raise triglycerides; beta-blockers and some antipsychotics do as well.
Age and sex. Triglycerides tend to rise gradually across the lifespan as metabolic function declines. Postmenopausal women often see triglyceride elevation due to loss of estrogen's protective effect on triglyceride metabolism (though estrogen therapy itself raises levels). Men with low testosterone can also see elevated triglycerides.
Reduce refined carbohydrate and added sugar. De novo lipogenesis — the conversion of dietary carbs into triglycerides — is the metabolic pathway that drives hepatic VLDL production. Removing refined carbohydrates (especially from beverages, ultra-processed foods, and desserts) reduces the substrate for this process and often yields 20–40% drops in triglycerides within 6–12 weeks. The effect is dose-dependent and insulin-sensitivity-dependent: people with metabolic syndrome or insulin resistance see the largest drops.
Reduce alcohol intake. Alcohol is metabolized in the liver to acetyl-CoA, which is directly shunted into triglyceride synthesis. Even moderate daily alcohol reliably raises triglycerides; heavy drinkers often have severe hypertriglyceridemia. Reducing or eliminating alcohol often yields 30–50% drops in triglycerides.
Increase aerobic training volume and intensity. Aerobic exercise (steady-state or HIIT) improves whole-body insulin sensitivity and directly upregulates lipoprotein lipase — the enzyme that clears triglyceride-rich particles from the bloodstream. Regular aerobic training (≥150 min/week moderate intensity) produces meaningful triglyceride reductions, often amplified when combined with weight loss.
Achieve and maintain healthy body composition. Weight loss in people with excess adiposity reduces hepatic fat content and improves hepatic and peripheral insulin sensitivity. Even 5–10% body weight loss can meaningfully reduce triglycerides. The effect is driven by reduced hepatic lipid spillover — when fat tissue shrinks, it releases less fatty acid into the portal circulation, and the liver reduces VLDL production in response.
Optimize fructose intake. Fructose is metabolized directly by the liver and is uniquely potent at driving de novo lipogenesis and triglyceride synthesis — more so than glucose. Limiting added sugars (especially high-fructose corn syrup and other added fructose sources) can produce disproportionate triglyceride drops in susceptible individuals.
Increase soluble fiber intake. Soluble fiber (from legumes, oats, apples) binds bile acids in the gut and reduces their reabsorption. This forces the liver to synthesize new bile acids from cholesterol, which upregulates hepatic LDL receptors and improves whole-body lipid clearance. While the effect on triglycerides is modest compared to carbohydrate reduction, it's synergistic.
Pharmacology: fibrates and statins. Fibrates (fenofibrate, bezafibrate) activate PPAR-α and directly increase lipoprotein lipase activity and triglyceride clearance; they typically reduce triglycerides 20–50% and raise HDL. Statins also lower triglycerides modestly (10–20%), though their primary target is LDL and ApoB. In people with high triglycerides and low HDL alongside metabolic syndrome, fibrates are often preferred. GLP-1 receptor agonists (semaglutide, tirzepatide) improve insulin sensitivity and reduce hepatic lipogenesis and have emerged as powerful triglyceride-lowering agents in people with metabolic dysfunction.
The right lever depends on your genetic predisposition, baseline metabolic state, and full biomarker context. Severe insulin resistance with marked triglyceride elevation often requires combined dietary change and pharmacology. Mild elevation in someone with good metabolic health may respond to carbohydrate and alcohol reduction alone. A Loovi longevity doctor evaluates your whole profile — HbA1c, ApoB, HDL, metabolic history, family genetics — and maps the most efficient intervention path.
Triglycerides alone tell an incomplete story. A person with elevated triglycerides and low ApoB might simply have large, buoyant VLDL particles that pose lower atherogenic risk than expected. Another person with normal triglycerides but elevated ApoB and low HDL might have a more atherogenic particle distribution despite the TG number looking fine. This is why interpreting triglycerides alongside ApoB, LDL, HDL, and HbA1c is clinically essential — the pattern across markers reveals the true metabolic phenotype and atherogenic risk.
Moreover, elevated triglycerides often cluster with elevated blood pressure, reduced HDL, elevated glucose, and central obesity — the metabolic syndrome constellation. Testing one without the others means you miss the full scope of metabolic dysfunction and the urgency of intervening. A Loovi membership solves this by measuring 120+ biomarkers annually, mapping your full metabolic and cardiovascular profile, and revealing exactly which levers — nutrition, training, pharmacology — will move your numbers most efficiently. You get a consultation with a longevity doctor who contextualizes your triglycerides within your whole biomarker landscape, physical tests, and personal goals.
This pattern typically indicates large, buoyant VLDL particles carrying the triglycerides. Particle size matters for atherogenicity — large VLDL particles are less likely to penetrate the arterial wall than small, dense ones. However, even with normal ApoB, elevated triglycerides still reflect insulin resistance and metabolic dysfunction. The good news: if your ApoB is normal, you have fewer atherogenic particles, so your absolute cardiovascular risk is lower than if both were elevated. But you should still address the underlying insulin resistance through dietary and lifestyle change, because the metabolic pattern will likely worsen over time if uncorrected.
This suggests you have more LDL and IDL particles relative to VLDL particles — a pattern sometimes called isolated ApoB elevation. Your particle count is still high (meaning more atherogenic particles in circulation), but your liver isn't overproducing triglycerides. This can occur with normal insulin sensitivity but genetically higher LDL production, or with metabolic patterns that bias toward LDL rather than VLDL production. The cardiovascular risk is driven by the high ApoB, not the normal triglycerides. Managing this usually requires medication (statin, ezetimibe, PCSK9 inhibitor) or genetic investigation for familial hypercholesterolemia.
Increasingly, yes. Non-fasting (postprandial) triglycerides are now understood to be a stronger predictor of cardiovascular events than fasting levels in many populations. This reflects real biology — your blood spends most of the day in a fed state, not fasting. A non-fasting triglyceride >2.0 mmol/L correlates with elevated event risk, whereas a fasting level of 1.5–2.0 mmol/L might be considered borderline. The ESC now recommends including non-fasting triglycerides in risk assessment. That said, fasting levels remain standard in Swedish healthcare, so if that's what you're testing, aim for <1.0 mmol/L for optimal metabolic health.
Triglyceride levels can drop 20–40% within 2–4 weeks of removing refined carbohydrates and alcohol — sometimes faster in insulin-resistant individuals. This reflects the rapid reduction in hepatic lipogenesis when dietary substrate is removed. Aerobic training produces measurable drops within 6–8 weeks, and weight loss adds incremental benefit. The exact timeline depends on baseline severity and adherence. Some people see 50% drops within weeks; others with genetic forms of hypertriglyceridemia may see smaller responses and require medication. The key point: triglycerides are one of the most responsive markers to intervention, making them excellent for early feedback on whether your metabolic strategy is working.
Very low triglycerides (<0.3 mmol/L) are rare and usually reflect either very low carbohydrate intake, genetic lipoprotein lipase deficiency causing impaired synthesis, malabsorption, malnutrition, or severe liver disease. In otherwise healthy people eating a low-carb diet, very low triglycerides are benign. In sick patients or those with genetic causes, very low triglycerides can signal metabolic or nutritional trouble. Context matters — check with a doctor if your triglycerides are unexpectedly low alongside other concerning symptoms.
Statins lower triglycerides modestly — usually 10–20% — but they're not the primary drug for triglyceride management. Fibrates (fenofibrate, bezafibrate) are more potent, typically reducing triglycerides 20–50%. GLP-1 receptor agonists lower both triglycerides and body weight, especially in insulin-resistant patients. The choice of drug depends on your full biomarker profile: if LDL and ApoB are high, a statin is usually first-line; if triglycerides are extremely high or you have metabolic syndrome with low HDL, a fibrate may be preferred. Often both are used together.
After you eat carbohydrates or fat, your intestines absorb the nutrients, and your liver ramps up VLDL production to distribute them. In insulin-sensitive people with normal metabolism, this postprandial lipemia is transient — triglycerides rise for a few hours, then clear efficiently as the body absorbs and uses nutrients. In insulin-resistant people, lipoprotein lipase activity is reduced and VLDL clearance is slow, so triglycerides stay elevated longer and higher. A meal rich in refined carbs or fructose produces an exaggerated postprandial spike compared to a meal with protein, fat, and fiber. This is why testing non-fasting triglycerides 2–4 hours after a meal can reveal insulin resistance that fasting levels miss.
Yes — fasting triglycerides are standard at most vårdcentral and are usually included in routine lipid panels alongside LDL, HDL, and total cholesterol. They're covered by Swedish health insurance. Non-fasting triglycerides and repeated testing may require private services or a longevity membership like Loovi, which tests triglycerides annually as part of comprehensive 120+ biomarker screening. If your triglycerides are abnormal, your doctor will discuss retesting frequency and intervention strategies.
Triglycerides >10 mmol/L create acute lipemia and pancreatitis risk. This is a medical emergency requiring urgent evaluation and treatment. At these levels, blood becomes visibly cloudy (milky), pancreatic inflammation is likely, and hospitalization may be needed. Triglycerides 5.6–10 mmol/L require urgent intervention and investigation for genetic causes, severe uncontrolled diabetes, or other secondary triggers, but not necessarily emergency admission. If your triglycerides are >5.6 mmol/L, contact your doctor immediately. If >10 mmol/L, seek emergency care.
